Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shandong Weigao Blood Purification Products Co (SHSE:603014) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Shandong Weigao Blood Purification Products Co Receivables Turnover Related Terms
Shandong Weigao Blood Purification Products Co Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Weigao Blood Purification Products Co Receivables Turnover Chart
Shandong Weigao Blood Purification Products Co Annual Data
SHSE:603014 vs ABT, SYK, MDT: Receivables Turnover Comparison
For the Medical Devices subindustry, Shandong Weigao Blood Purification Products Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shandong Weigao Blood Purification Products Co Receivables Turnover vs Medical Devices & Instruments Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Weigao Blood Purification Products Co (SHSE:603014) has a Receivables Turnover of 1.01 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Shandong Weigao Blood Purification Products Co and its competitors. According to the industry distribution chart, Shandong Weigao Blood Purification Products Co ranks #574 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 70.7%.
Is Shandong Weigao Blood Purification Products Co's Receivables Turnover too high?
Shandong Weigao Blood Purification Products Co's current Receivables Turnover is 1.01. The Medical Devices & Instruments industry median Receivables Turnover is 5.58. Shandong Weigao Blood Purification Products Co's value of 1.01 is 81.9% below this industry median. Based on the distribution chart, Shandong Weigao Blood Purification Products Co ranks #574 out of 812 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Shandong Weigao Blood Purification Products Co has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Shandong Weigao Blood Purification Products Co's Receivables Turnover compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shandong Weigao Blood Purification Products Co ranks #574 out of 812 companies for Receivables Turnover. This places Shandong Weigao Blood Purification Products Co in the lower half of its industry. The industry median Receivables Turnover is 5.58. Shandong Weigao Blood Purification Products Co's value of 1.01 is 81.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.58, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shandong Weigao Blood Purification Products Co's current Receivables Turnover of 1.01 is 81.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Shandong Weigao Blood Purification Products Co and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shandong Weigao Blood Purification Products Co's current Receivables Turnover is 1.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Weigao Blood Purification Products Co stock overvalued right now?
Shandong Weigao Blood Purification Products Co (SHSE:603014) has a current Receivables Turnover of 1.01. The current Receivables Turnover is 1.01 and 81.9% below the Medical Devices & Instruments industry median of 5.58. Shandong Weigao Blood Purification Products Co's overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Shandong Weigao Blood Purification Products Co (SHSE:603014), the current Receivables Turnover is 1.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603014 has been successfully added to your 
